Ozarelix (developmental code names D-63153, SPI-153) is a peptide gonadotropin-releasing hormone antagonist (GnRH antagonist) which is or was under development by AEterna Zentaris Inc. and Spectrum Pharmaceuticals as a long-acting injection formulation for the treatment of prostate cancer.

[1] The drug was previously under investigation for the treatment of benign prostatic hyperplasia and Alzheimer's disease as well, but development for these indications was discontinued.

[1] As of June 2015, it was in phase II clinical trials for prostate cancer.

[1] This drug article relating to the genito-urinary system is a stub.

You can help Wikipedia by expanding it.This hormonal preparation article is a stub.